Upregulation of PD-L1 by many tumors enables subversion of the PD-1/PD-L1 pathway, sufficient to blunt cytotoxic T-cell response within the tumor microenvironment, and has been associated with a poor prognosis [1–4]. Here, PDCD1 is linked to neoplasm.